Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2018 · 10-Q
Revenue$75.54M$75.54M+30.4% vs Q3 2017 Net Income$2.39M$2.39M+2,313.1% vs Q3 2017 EPS Diluted$0.05$0.05— vs Q3 2017 Gross Profit$29,260,000+42.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$15,781,000+538.4% Free Cash Flowderived$3,146,000N/M Margins · derivedGross margin38.7%+3.2 pt vs Q3 2017
Operating margin3.4%+8.5 pt vs Q3 2017
Net margin3.2%+3.0 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 9, 2018 · 40 d after period end